{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:53:25Z","timestamp":1768002805089,"version":"3.49.0"},"reference-count":76,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Selective internal radiation therapy (SIRT) is part of the treatment strategy for hepatocellular carcinoma (HCC). Strong clinical data demonstrated the effectiveness of this therapy in HCC with a significant improvement in patient outcomes. Recent studies demonstrated a strong correlation between the tumor response and the patient outcome when the tumor-absorbed dose was assessed by nuclear medicine imaging. Dosimetry plays a key role in predicting the clinical response and can be optimized using a personalized method of activity planning (multi-compartmental dosimetry). This paper reviews the main clinical results of SIRT in HCC and emphasizes the central role of dosimetry for improving it effectiveness. Moreover, some patient and tumor characteristics predict a worse outcome, and toxicity related to SIRT treatment of advanced HCC patient selection based on the performance status, liver function, tumor characteristics, and tumor targeting using technetium-99m macro-aggregated albumin scintigraphy can significantly improve the clinical performance of SIRT.<\/jats:p>","DOI":"10.3390\/curroncol29040196","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T21:40:14Z","timestamp":1648590014000},"page":"2422-2434","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7725-2527","authenticated-orcid":false,"given":"Philippe","family":"d\u2019Abadie","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Cliniques Universitaires Saint Luc, Universit\u00e9 Catholique de Louvain, 1200 Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0120-684X","authenticated-orcid":false,"given":"Stephan","family":"Walrand","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Cliniques Universitaires Saint Luc, Universit\u00e9 Catholique de Louvain, 1200 Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Lhommel","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Cliniques Universitaires Saint Luc, Universit\u00e9 Catholique de Louvain, 1200 Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9434-751X","authenticated-orcid":false,"given":"Michel","family":"Hesse","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Cliniques Universitaires Saint Luc, Universit\u00e9 Catholique de Louvain, 1200 Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Borbath","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Cliniques Universitaires Saint Luc, Universit\u00e9 Catholique de Louvain, 1200 Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Jamar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Cliniques Universitaires Saint Luc, Universit\u00e9 Catholique de Louvain, 1200 Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jvir.2016.09.024","article-title":"Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions","volume":"28","author":"Padia","year":"2017","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1055\/s-2006-939842","article-title":"Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver","volume":"23","author":"Lewandowski","year":"2006","journal-title":"Semin. Interv. Radiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.ijrobp.2004.09.004","article-title":"Pathologic response and microdosimetry of (90)Y microspheres in man: Review of four explanted whole livers","volume":"60","author":"Kennedy","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_4","first-page":"178","article-title":"Radioembolization of hepatic tumors","volume":"5","author":"Kennedy","year":"2014","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"D\u2019Abadie, P., Hesse, M., Louppe, A., Lhommel, R., Walrand, S., and Jamar, F. (2021). Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects. Molecules, 26.","DOI":"10.3390\/molecules26133966"},{"key":"ref_6","unstructured":"SIR-Spheres (2019). Instructions for Use, SIRTeX Medical Limited. Available online: https:\/\/www.sirtex.com\/us\/clinicians\/instructions-for-use\/."},{"key":"ref_7","unstructured":"(2022, March 09). Therasphere. Instructionsforuse. Available online: https:\/\/www.bostonscientific.com\/en-EU\/products\/selective-internal-radiation-therapy\/therasphere-y90-glass-microspheres.html."},{"key":"ref_8","unstructured":"QuiremSpheres (2022, March 09). Instruction for Use. Available online: https:\/\/www.quirem.com\/wp-content\/uploads\/2022\/01\/LC-8004307-IFU-QuiremSpheres-Multi-Language.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40658-018-0221-z","article-title":"The physics of radioembolization","volume":"5","author":"Bastiaannet","year":"2018","journal-title":"EJNMMI Phys."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"592529","DOI":"10.3389\/fonc.2021.592529","article-title":"Yttrium-90 TOF-PET-Based EUD Predicts Response Post Liver Radioembolizations Using Recommended Manufacturer FDG Reconstruction Parameters","volume":"11","author":"Hesse","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update","volume":"76","author":"Reig","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12072-018-9919-1","article-title":"Goals and targets for personalized therapy for HCC","volume":"13","author":"Couri","year":"2019","journal-title":"Hepatol. Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","article-title":"Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100129","DOI":"10.1016\/j.esmoop.2021.100129","article-title":"Locoregional therapy in hepatocellular carcinoma: When to start and when to stop and when to revisit","volume":"6","author":"Lee","year":"2021","journal-title":"ESMO Open"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7315","DOI":"10.2147\/OTT.S175715","article-title":"Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: A meta-analysis of randomized trials","volume":"11","author":"Tamburini","year":"2018","journal-title":"Onco Targets Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): An open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.2967\/jnumed.120.242933","article-title":"NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with (90)Y Resin Microspheres Versus Sorafenib in Advanced Hepatocellular Carcinoma","volume":"61","author":"Venerito","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s00270-014-1012-0","article-title":"Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma","volume":"38","author":"Pitton","year":"2015","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma","volume":"71","author":"Ricke","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_24","unstructured":"De La Torre-Alaez, M., Matilla, A., Varela, M., Inarrairaegui, M., Reig, M., Lledo, J., Arenas, J., Lorente, S., Testillano, M., and Gomez-Martin, C. (2020, January 11\u201313). Nivolumab after selective internal radiation therapy using sir spheres resin microspheres in patients with hepatcocellular carcinoma: The NASIR HCC trial. Proceedings of the International Liver Cancer Association 2020 Virtual Conference, Oral Communication, Virtual Conference."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","article-title":"Radioembolization with Y90-resin micropsheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): A single arm, single centre, phase 2 trial","volume":"6","author":"Tai","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"568759","DOI":"10.3389\/fimmu.2020.568759","article-title":"Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond","volume":"11","author":"Lee","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2967\/jnumed.110.075861","article-title":"Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: Radiobiologic considerations","volume":"51","author":"Strigari","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1148\/radiol.2020191606","article-title":"Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with (90)Y in the SARAH Study","volume":"296","author":"Hermann","year":"2020","journal-title":"Radiology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2967\/jnumed.119.226472","article-title":"Prediction of Tumor Control in (90)Y Radioembolization by Logit Models with PET\/CT-Based Dose Metrics","volume":"61","author":"Dewaraja","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"245010","DOI":"10.1088\/1361-6560\/aaf205","article-title":"(90)Y TOF-PET based EUD reunifies patient survival prediction in resin and glass microspheres radioembolization of HCC tumours","volume":"63","author":"Hesse","year":"2018","journal-title":"Phys. Med. Biol."},{"key":"ref_31","first-page":"168","article-title":"Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: The experience of the National Tumor Institute of Milan","volume":"55","author":"Chiesa","year":"2011","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2967\/jnumed.111.094235","article-title":"Dosimetry based on 99mTc-macroaggregated albumin SPECT\/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: Preliminary results","volume":"53","author":"Garin","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/liv.13220","article-title":"High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with (90) Y-loaded glass microsphere radioembolization","volume":"37","author":"Garin","year":"2017","journal-title":"Liver. Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ijrobp.2018.05.062","article-title":"Hepatocellular Carcinoma Tumor Dose Response After (90)Y-radioembolization With Glass Microspheres Using (90)Y-SPECT\/CT-Based Voxel Dosimetry","volume":"102","author":"Kappadath","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.jvir.2018.07.006","article-title":"Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma","volume":"29","author":"Allimant","year":"2018","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ijrobp.2018.01.116","article-title":"Prospective Trial Using Internal Pair-Production Positron Emission Tomography to Establish the Yttrium-90 Radioembolization Dose Required for Response of Hepatocellular Carcinoma","volume":"101","author":"Chan","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol Phys."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/MNM.0000000000001395","article-title":"Prediction of tumor response and patient outcome after radioembolization of hepatocellular carcinoma using 90Y-PET-computed tomography dosimetry","volume":"42","author":"Walrand","year":"2021","journal-title":"Nucl. Med. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1038\/s41598-021-82887-w","article-title":"Diagnostic and prognostic value of (99m)Tc-MAA SPECT\/CT for treatment planning of (90)Y-resin microsphere radioembolization for hepatocellular carcinoma: Comparison with planar image","volume":"11","author":"Son","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13550-021-00766-x","article-title":"Impact of contouring methods on pre-treatment and post-treatment dosimetry for the prediction of tumor control and survival in HCC patients treated with selective internal radiation therapy","volume":"11","author":"Nodari","year":"2021","journal-title":"EJNMMI Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): A randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.2967\/jnumed.117.202937","article-title":"Retrospective Voxel-Based Dosimetry for Assessing the Ability of the Body-Surface-Area Model to Predict Delivered Dose and Radioembolization Outcome","volume":"59","author":"Kafrouni","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejmp.2021.07.032","article-title":"Accurate non-tumoral 99mTc-MAA absorbed dose prediction to plan optimized activities in liver radioembolization using resin microspheres","volume":"89","author":"Walrand","year":"2021","journal-title":"Phys. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Garin, E., Palard, X., and Rolland, Y. (2020). Personalised Dosimetry in Radioembolisation for HCC: Impact on Clinical Outcome and on Trial Design. Cancers, 12.","DOI":"10.3390\/cancers12061557"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1007\/s00259-020-04845-4","article-title":"Radioembolization of hepatocarcinoma with (90)Y glass microspheres: Treatment optimization using the dose-toxicity relationship","volume":"47","author":"Chiesa","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40658-021-00394-3","article-title":"EANM dosimetry committee series on standard operational procedures: A unified methodology for (99m)Tc-MAA pre- and (90)Y peri-therapy dosimetry in liver radioembolization with (90)Y microspheres","volume":"8","author":"Chiesa","year":"2021","journal-title":"EJNMMI Phys."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2967\/jnumed.117.199752","article-title":"(90)Y Radioembolization for Locally Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Long-Term Outcomes in a 185-Patient Cohort","volume":"59","author":"Abouchaleh","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00270-020-02434-4","article-title":"Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent?","volume":"43","author":"Zu","year":"2020","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes","volume":"138","author":"Salem","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2967\/jnumed.114.145177","article-title":"Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis","volume":"56","author":"Garin","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2017.12.026","article-title":"Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion","volume":"68","author":"Spreafico","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11605-009-1085-2","article-title":"Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection","volume":"14","author":"Dinant","year":"2010","journal-title":"J. Gastrointest. Surg."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13550-016-0248-x","article-title":"Hepatobiliary scintigraphy may improve radioembolization treatment planning in HCC patients","volume":"7","author":"Braat","year":"2017","journal-title":"EJNMMI Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fonc.2014.00152","article-title":"Monitoring of Total and Regional Liver Function after SIRT","volume":"4","author":"Bennink","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"20150943","DOI":"10.1259\/bjr.20150943","article-title":"Yttrium-90 hepatic radioembolization: Clinical review and current techniques in interventional radiology and personalized dosimetry","volume":"89","author":"Tong","year":"2016","journal-title":"Br. J. Radiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jvir.2009.01.021","article-title":"Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization","volume":"20","author":"Louie","year":"2009","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"768","DOI":"10.5152\/dir.2021.20785","article-title":"Antireflux catheter improves tumor targeting in liver radioembolization with resin microspheres","volume":"27","author":"Walrand","year":"2021","journal-title":"Diagn. Interv. Radiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/1097-0142(19850115)55:2<311::AID-CNCR2820550202>3.0.CO;2-M","article-title":"Changes in distribution of hepatic blood flow induced by intra-arterial infusion of angiotensin II in human hepatic cancer","volume":"55","author":"Sasaki","year":"1985","journal-title":"Cancer"},{"key":"ref_58","first-page":"G253","article-title":"Shear-induced modulation of vasoconstriction in the hepatic artery and portal vein by nitric oxide","volume":"274","author":"Macedo","year":"1998","journal-title":"Am. J. Physiol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Walrand, S., Hesse, M., d\u2019Abadie, P., and Jamar, F. (2021). Hepatic Arterial Buffer Response in Liver Radioembolization and Potential Use for Improved Cancer Therapy. Cancers, 13.","DOI":"10.20944\/preprints202102.0229.v1"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Lautt, W.W. (2009). Hepatic Circulation: Physiology and Pathophysiology. Colloquium Series on Integrated Systems Physiology: From Molecule to Function to Disease, Morgan & Claypool.","DOI":"10.4199\/C00004ED1V01Y200910ISP001"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"30C","DOI":"10.1016\/S0002-9149(88)80064-X","article-title":"Changes in regional blood flow distribution induced by infusions of dopexamine hydrochloride or dobutamine in anesthetized dogs","volume":"62","author":"Biro","year":"1988","journal-title":"Am. J. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"308","DOI":"10.2165\/00003495-199039020-00009","article-title":"Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency","volume":"39","author":"Fitton","year":"1990","journal-title":"Drugs"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s00259-020-05163-5","article-title":"International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres","volume":"48","author":"Levillain","year":"2021","journal-title":"Eur.J. Nucl. Med. Mol. Imaging"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/hep.31159","article-title":"Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients with Cirrhosis","volume":"72","author":"Rich","year":"2020","journal-title":"Hepatology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"W260","DOI":"10.2214\/AJR.11.6995","article-title":"Value of PET\/CT in the management of primary hepatobiliary tumors, part 2","volume":"197","author":"Sacks","year":"2011","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00261-015-0603-9","article-title":"Prognostic significance of parameters from pretreatment (18)F-FDG PET in hepatocellular carcinoma: A meta-analysis","volume":"41","author":"Sun","year":"2016","journal-title":"Abdom. Radiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"10406","DOI":"10.3748\/wjg.v22.i47.10406","article-title":"Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization","volume":"22","author":"Abuodeh","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s00259-017-3653-0","article-title":"(18)F-FDG PET\/CT predicts survival after (90)Y transarterial radioembolization in unresectable hepatocellular carcinoma","volume":"44","author":"Jreige","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Antkowiak, M., Gabr, A., Das, A., Ali, R., Kulik, L., Ganger, D., Moore, C., Abecassis, M., Katariya, N., and Mouli, S. (2019). Prognostic Role of Albumin, Bilirubin, and ALBI Scores: Analysis of 1000 Patients with Hepatocellular Carcinoma Undergoing Radioembolization. Cancers, 11.","DOI":"10.3390\/cancers11060879"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"840","DOI":"10.21037\/jgo.2018.05.14","article-title":"Using the Albumin-Bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinoma","volume":"9","author":"Mohammadi","year":"2018","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Lescure, C., Estrade, F., Pedrono, M., Campillo-Gimenez, B., Le Sourd, S., Pracht, M., Palard, X., Bourien, H., Muzellec, L., and Uguen, T. (2021). ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13153794"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s00270-017-1791-1","article-title":"Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion\/Metastases","volume":"41","author":"Ali","year":"2018","journal-title":"Cardiovasc. Intervent. Radiol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/4\/196\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:45:54Z","timestamp":1760136354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/4\/196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":76,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["curroncol29040196"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29040196","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,29]]}}}